Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biperiden. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | HRH1 | P35367 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biperiden SCHEMBL18281119 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL20229362 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL20211718 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL18281117 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL13898507 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL23697535 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL16449751 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL16449749 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL6775788 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 | |
| Biperiden SCHEMBL20229360 | 0.99 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 992 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-20200330500-A1 | Mecobalamin for Relieving Emergency Drug Poisoning | CHENG EN CHE (TW) | 2020-10-22 | — | — | US | claimed |
| US-20190351029-A1 | MODULATION OF ISCHEMIC CELL BIOENERGETICS | EAST CAROLINA UNIVERSITY | 2019-11-21 | — | — | US | claimed |
| CN-106187948-B | Biperiden hydrochloride preparation method | 安徽省逸欣铭医药科技有限公司 | 2019-02-22 | — | — | CN | claimed |
| WO-2018148743-A1 | MODULATION OF ISCHEMIC CELL BIOENERGETICS | EAST CAROLINA UNIVERSITY (US) | 2018-08-16 | — | — | WO | claimed |
| CN-106187948-A | The preparation method that biperiden hydrochloride is new | 安徽省逸欣铭医药科技有限公司 | 2016-12-07 | — | — | CN | claimed |
| EP-2173344-B1 | TREATMENT OR PROPHYLAXIS OR NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | CLARENCEW PTY LTD (AU) | 2016-04-06 | — | — | EP | claimed |
| EP-1528917-B1 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LTD (IN) | 2013-06-19 | — | — | EP | claimed |
| US-7829116-B2 | Silylated polyurethanes; pressure sensitive adhesives; transdermal drug delivery | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2010-11-09 | — | — | US | claimed |
| WO-2004012700-A2 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-02-12 | — | — | WO | claimed |
| US-6217905-B1 | Antiparkinson dosage form | ALZA CORPORATION | 2001-04-17 | — | — | US | claimed |
| US-6146656-A | COMPRISING A SKIN CONTACT BASE CONTAINING BIPERIDEN-HCL AND A FREEING AGENT, THE SKIN CONTACT BASE IS PRESSURE SENSITIVE ADHESIVE LAYER HAVING ADHESION AT ROOM TEMPERATURE ON ONE SIDE OF A BACKING MATERIAL; FOR TREATING PARKINSON'S DISEASE | NITTO DENKO CORPORATION (JP) | 2000-11-14 | — | — | US | claimed |
| EP-0527835-B1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORP (US) | 1994-10-26 | — | — | EP | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| US-4945097-A | THERAPY FOR ANOXIA, HYPOXIA, OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-07-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CHRM1 1068/4885CHRM2 2141/4885CYP2D6 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.